Herbal Drug Registration and Regulatory Documentation

Herbal drug registration, irrespective of the specific national pathway pursued, requires the compilation of a structured regulatory dossier documenting botanical identity, manufacturing process, quality specifications, safety data, and, where therapeutic claims are made, efficacy evidence. The internationally harmonised Common Technical Document (CTD) format, adapted for herbal and phytopharmaceutical products, structures this dossier into defined modules addressing the drug substance and drug product separately. Module 3.2.S, covering the drug substance (the plant extract or isolated phytoconstituent itself), documents general botanical information including scientific name, plant part, geographical source, DNA barcode, and voucher specimen number; the manufacturing (extraction) process and solvent grade in accordance with ICH Q3C; full chemical characterisation including phytochemical content and chromatographic fingerprint; formal control specifications addressing appearance, moisture, ash values, marker content, heavy metals, microbial limits, and pesticide residues; the certified reference standard used for marker quantification; and container closure and storage conditions supporting the claimed shelf-life. Module 3.2.P, covering the finished drug product, documents the quantitative formulation including the extract-to-drug ratio and the function of each excipient; the pharmaceutical development rationale, frequently supported by documented traditional use precedent; release specifications encompassing fingerprint identity, marker assay, and relevant pharmaceutical performance tests such as disintegration or dissolution; and formal stability data generated under the ICH Q1A(R2) conditions described in Phase 5.